PF-03550096

PF-03550096

Identifiers
IUPAC name N-[(1S)-1-(aminocarbonyl)-2,2-dimethylpropyl]-2,3-dihydro-3-(3-hydroxy-3-methylbutyl)-2-oxo-1H-benzimidazole-1-carboxamide
CAS Number	910376-39-5 Y
PubChem (CID)	24857887
ChemSpider	21378519
Chemical and physical data
Formula	C19H28N4O4
Molar mass	376.45 g/mol
3D model (Jmol)	Interactive image
SMILES O=C(N1C(N(CCC(C)(O)C)C2=C1C=CC=C2)=O)N[C@@H](C(C)(C)C)C(N)=O
InChI InChI=1S/C19H28N4O4/c1-18(2,3)14(15(20)24)21-16(25)23-13-9-7-6-8-12(13)22(17(23)26)11-10-19(4,5)27/h6-9,14,27H,10-11H2,1-5H3,(H2,20,24)(H,21,25)/t14-/m1/s1 Key:GGNIFXBIJCNXCT-CQSZACIVSA-N

PF-03550096 is a drug that acts as a potent agonist for the CB₂ cannabinoid receptor, with good selectivity over CB₁ having K_i values of 7nM at CB₂ and 1500nM at CB₁. It was originally developed by Pfizer in 2008 as a medication for irritable bowel syndrome,^[1] but has only progressed to animal studies.^[2]

See also

• AB-FUBINACA
• AB-PINACA

References

1. ↑ Ando K et al, BENZIMIDAZOLONE DERIVATIVES. WO 2008/032164
2. ↑ Kikuchi, A.; Ohashi, K.; Sugie, Y.; Sugimoto, H.; Omura, H. (2008). "Pharmacological evaluation of a novel cannabinoid 2 (CB2) ligand, PF-03550096, in vitro and in vivo by using a rat model of visceral hypersensitivity". Journal of pharmacological sciences. 106 (2): 219–224. doi:10.1254/jphs.FP0071599. PMID 18270474.